Introduction: Heart failure continues to be a significant source of morbidity and mortality despite advances in pharmacological therapies, devices, and mechanical circulatory support. Myocardial attrition, myocardial fibrosis, vascular dysfunction, inflammation, and ventricular remodeling represent a biological substrate that is not reversible with standard medical therapy and provide a rationale for regenerative approaches. Purpose: To examine the way in which potential mechanisms of action vary between stem cell-based technologies used in heart failure and to assess how cell type, disease state, administration route, dosage, outcomes selected, and safety impact the transition from laboratory science to clinical benefit. Method: Narrative review focused on mechanisms with searches of PubMed/MEDLINE and Google Scholar databases from inception to 31 August 2026 supplemented by screening of references from relevant reviews and primary papers. Synthesis of evidence was qualitative and organized by cellular platform and mechanism; no risk-of-bias scores were assigned nor pooled effect estimates produced. The final body of evidence included 81 papers, of which 11 were relevant clinical trials quantitatively summarized. Main body: Therapies based on adult stromal or progenitor cells have demonstrated poor engraftment with cardiomyocytes in the long term, which redirected efforts to explore the possible paracrine, angiogenic, immunomodulatory, and anti-fibrotic roles of such therapies. In contrast, pluripotent stem cell-derived cardiomyocytes represent a strategy for myocardial remuscularization. However, in this case, a significant number of issues arise regarding maturation, electrical coupling, arrhythmogenicity, immune compatibility, manufacturing, delivery, and safety over the long term. This review provides a critical evaluation of these two different therapeutic platforms along with their mechanisms, preclinical and clinical data, and translation obstacles. Conclusion: According to the data gathered thus far, there is no universal cell therapy for heart failure. Adult stromal and similar products act through mainly paracrine, vascular, immunomodulatory, and antifibrotic mechanisms, while pluripotent stem cell-derived cardiomyocytes are considered for myocardial remuscularization. In all cases, translation of biological effect into clinical efficacy depends on matching mechanism, proper patient selection, product characteristics, dosage, delivery, and safety over time. Therefore, future research should be aimed at distinction between preservation, repair, and regeneration, and biological hypotheses should correspond to clinical endpoints.